QuidelOrtho (NASDAQ:QDEL) Posts Earnings Results, Beats Estimates By $0.18 EPS

QuidelOrtho (NASDAQ:QDEL) posted its quarterly earnings results on Thursday. The company reported $0.13 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.05) by $0.18, FiscalAI reports. QuidelOrtho had a positive return on equity of 4.25% and a negative net margin of 45.57%.The business had revenue of $630.90 million for the quarter, compared to analyst estimates of $618.72 million. QuidelOrtho updated its FY 2026 guidance to 0.650-0.900 EPS.

QuidelOrtho Stock Down 6.7%

NASDAQ QDEL traded down $1.18 on Thursday, reaching $16.32. The company had a trading volume of 2,724,490 shares, compared to its average volume of 1,756,368. The firm has a market capitalization of $1.11 billion, a price-to-earnings ratio of -0.92 and a beta of 0.68. The company has a debt-to-equity ratio of 1.33, a quick ratio of 0.80 and a current ratio of 1.43. QuidelOrtho has a 1-year low of $9.92 and a 1-year high of $35.58. The company’s fifty day moving average is $15.70 and its 200-day moving average is $17.70.

Institutional Trading of QuidelOrtho

Institutional investors have recently modified their holdings of the company. Invesco Ltd. increased its position in QuidelOrtho by 87.0% during the third quarter. Invesco Ltd. now owns 2,906,763 shares of the company’s stock worth $85,604,000 after buying an additional 1,352,503 shares during the last quarter. Newtyn Management LLC increased its holdings in shares of QuidelOrtho by 58.3% in the third quarter. Newtyn Management LLC now owns 2,700,000 shares of the company’s stock valued at $79,515,000 after purchasing an additional 994,332 shares during the last quarter. Goldman Sachs Group Inc. raised its position in shares of QuidelOrtho by 101.2% in the fourth quarter. Goldman Sachs Group Inc. now owns 1,755,401 shares of the company’s stock valued at $50,134,000 after purchasing an additional 883,077 shares during the period. T. Rowe Price Investment Management Inc. lifted its stake in shares of QuidelOrtho by 7.4% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 11,832,098 shares of the company’s stock worth $337,925,000 after buying an additional 819,908 shares during the last quarter. Finally, State Street Corp boosted its holdings in shares of QuidelOrtho by 23.3% during the 2nd quarter. State Street Corp now owns 2,700,940 shares of the company’s stock worth $77,841,000 after buying an additional 510,291 shares during the period. 99.00% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on QDEL. JPMorgan Chase & Co. raised their target price on QuidelOrtho from $11.00 to $12.00 and gave the stock an “underweight” rating in a report on Wednesday, July 1st. UBS Group restated a “neutral” rating and set a $12.00 price objective on shares of QuidelOrtho in a report on Thursday, May 7th. Jefferies Financial Group reissued a “hold” rating on shares of QuidelOrtho in a research report on Monday, June 29th. Zacks Research upgraded shares of QuidelOrtho from a “strong sell” rating to a “hold” rating in a research report on Monday, June 15th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of QuidelOrtho in a research note on Friday, July 17th. Four investment analysts have rated the stock with a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Reduce” and an average target price of $13.62.

About QuidelOrtho

QuidelOrtho is a global diagnostics company formed through the merger of Quidel Corporation and Ortho Clinical Diagnostics. The combined entity develops, manufactures and markets a broad portfolio of rapid and high-throughput diagnostic solutions across immunoassay, molecular diagnostics and transfusion medicine. Its offerings span point-of-care platforms for acute care testing as well as large-scale automated systems designed for clinical laboratories and blood banks.

The company’s product range includes rapid antigen and antibody tests for infectious diseases, molecular assays utilizing nucleic acid amplification technology, and integrated immunodiagnostic analyzers.